Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

4.95
-0.5700-10.33%
Post-market: 4.94-0.0100-0.20%19:30 EDT
Volume:1.63M
Turnover:8.28M
Market Cap:395.94M
PE:-2.18
High:5.62
Open:5.53
Low:4.90
Close:5.52
52wk High:14.87
52wk Low:4.90
Shares:79.99M
Float Shares:35.75M
Volume Ratio:1.73
T/O Rate:4.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2730
EPS(LYR):-4.3039
ROE:-81.92%
ROA:-47.10%
PB:1.23
PE(LYR):-1.15

Loading ...

JPMorgan cuts BridgeBio target, sees buying opportunity on selloff

TIPRANKS
·
Sep 11

U.S. Research Roundup-Caseys General Stores, Targa Resources, United Rentals

Reuters
·
Sep 10

BridgeBio Oncology Therapeutics (BBOT) Receives a Buy from Wedbush

TIPRANKS
·
Sep 09

BridgeBio Oncology Thera Price Target Maintained with a $25.00/Share by Wedbush

Dow Jones
·
Sep 09

BridgeBio Oncology price target lowered to $20 from $23 at Canaccord

TIPRANKS
·
Sep 09

BridgeBio Oncology Therapeutics Inc : Stifel Cuts Target Price to $15 from $23

THOMSON REUTERS
·
Sep 09

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Sep 09

BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results

MT Newswires Live
·
Sep 09

BridgeBio Oncology Therapeutics Releases RAS-Pathway Therapeutics Corporate Update Deck

Reuters
·
Sep 09

BridgeBio Oncology Therapeutics - Bbo-8520 Monotherapy Shows 63% Orr, 100% Dcr in 2L+ Krasg12c Nsclc

THOMSON REUTERS
·
Sep 09

BridgeBio Oncology Therapeutics - Bbo-11818 and Bbo-10203 Monotherapy Data Update Expected in Q4 2026

THOMSON REUTERS
·
Sep 09

Bbot Announces New Bbo-8520 Data; Highlights Strategic Focus on 2L+ Nsclc Bbo-8520 Combination as Well as Bbo-11818 and Bbo-10203 Combinations in Kras-Mutant Cancers

THOMSON REUTERS
·
Sep 09

BridgeBio Oncology Therapeutics - Expanded Bbo-8520 Plus Pembrolizumab Dataset Expected in Mid-2027

THOMSON REUTERS
·
Sep 09

BridgeBio Oncology Therapeutics - May Offer up to $500 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Sep 02

BBOT to Participate in Upcoming Investor Healthcare Conferences

GlobeNewswire
·
Sep 02

BridgeBio Oncology Therapeutics (BBOT) Receives a New Rating from Wedbush

TIPRANKS
·
Aug 12

Analysts Offer Insights on Healthcare Companies: 908 Devices (MASS), Pediatrix Medical Group (MD) and BridgeBio Oncology Therapeutics (BBOT)

TIPRANKS
·
Aug 12

BridgeBio Oncology Therapeutics Beri Opsi Saham 65.350 Lembar Kepada Dua Karyawan Baru Dengan Harga Pelaksanaan USD 9,28

Reuters
·
Aug 12

BridgeBio Oncology Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 12

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 12